Bronchitis Therapeutics - Pipeline Analysis 2018

Bronchitis Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS10987
Available Format:

Bronchitis therapeutic pipeline is likely to experience a positive trend in future due to decreasing quality of the air and increasing smoking. Prevalence of bronchitis is increasing due to environmental factors, genetic factors, infections, industrial pollution, less physical activity and smoking. Some of the main factors driving the pipeline analysis for bronchitis include increasing treatment cost, increasing high rate of hospitalizations due to chronic bronchitis, increasing alpha-1-antitrypsin (AAt) deficiency, low market penetration of effective drugs and increasing health awareness. According to Centers for Disease Control and Prevention, around 9.3 million people were diagnosed with chronic bronchitis in U.S in 2015. Chronic bronchitis is the third leading cause of deaths in the U.S. According to the data by American Lung Association (ALA) the risk of chronic bronchitis increases with age. Among people over 65 years old, the rate is 64.2 per 1,000 persons. For the people aged between 18 to 44year, the rate was 28.6 per 1,000 persons. The rate at which the disease affects the females is almost double, as compared to males.

Bronchitis is a condition which involves inflammation of bronchial tubes due to infection. This results in much more mucus with cough. There are two types of bronchitis, acute bronchitis and chronic bronchitis. Acute bronchitis is usually more common form of bronchitis which does not cause much problems. It includes common cold or flu which lasts for few days or weeks. Chronic bronchitis can also result in chronic obstructive pulmonary disease (COPD). Bronchitis is caused by either viruses, bacteria, or other irritant particles such as dust, fumes, air pollution and others, same as in the case of cold or flu. The production of more mucus results in problem in breathing with smaller opening for air to flow. The symptoms of bronchitis include fever, chest congestion, breath shortening, body aches, wheezing sound while breathing, headaches, cough with mucus and runny nose. Bronchitis is diagnosed by lung function test, chest X-ray, blood test, mucus testing and measuring oxygen levels in blood. The disease can be treated by using inhalers, bronchodilators, oxygen therapy, anti-inflammatory medicines, glucocorticoid steroids, antibiotics and over-the-counter pain relievers. Some of the home remedies can also be used to treat bronchitis like steam and drinking more water.

Many companies are developing drug for bronchitis which have shown promising result in clinical trials. SolAeroMed Inc. is developing a drug by the name S1226 for the improvement of bronchitis. S1226 is being developed as a small molecule, which acts as a cell membrane permeability enhancers. It is currently in the Phase II stage of development. Novartis AG is currently developing QBW251, which is in Phase II stage of clinical trial. It is being developed as a small molecule which acts as a cystic fibrosis transmembrane conductance regulator stimulants.

Some of the companies having a pipeline of bronchitis therapeutics include EmeraMed Ltd., Vertex Pharmaceuticals Incorporated, SolAeroMed Inc., Novartis AG, AstraZeneca Plc, F. Hoffmann-La Roche Ltd., Dompé Farmaceutici S.p.A, Invion Limited, Mucosis B.V.

Place An Order

Single User License

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry